INOZYME PHARMA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.565 USD | +0.11% |
|
-0.87% | +7.04% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 282M |
|---|---|---|---|---|---|
| Net income 2024 * | -101M | Net income 2025 * | -122M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.87
x | P/E ratio 2025 * |
-2.86
x | Employees | 59 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.48% |
More Fundamentals
* Assessed data
More news
Latest transcript on Inozyme Pharma, Inc.
More recommendations
More press releases
| 1 day | -2.56% | ||
| 1 week | -3.59% | ||
| Current month | +3.40% | ||
| 1 month | +3.64% | ||
| 3 months | -20.14% | ||
| 6 months | +23.24% | ||
| Current year | +7.04% |
1 week
4.54
4.82
1 month
4.184.90
Current year
4.037.80
1 year
2.697.80
3 years
0.9919.58
5 years
0.9931.65
10 years
0.9931.65
| Managers | Title | Age | Since |
|---|---|---|---|
Axel Bolte
FOU | Founder | 52 | 15-08-31 |
Doug Treco Treco
CEO | Chief Executive Officer | 66 | 20-04-30 |
| Director of Finance/CFO | 48 | 22-03-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Doug Treco Treco
CEO | Chief Executive Officer | 66 | 20-04-30 |
Reinaldo Diaz
BRD | Director/Board Member | 70 | 16-12-31 |
Axel Bolte
FOU | Founder | 52 | 15-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.53% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 4.565 | +0.11% | 202 069 |
| 24-05-23 | 4.56 | -2.56% | 312,405 |
| 24-05-22 | 4.68 | -0.43% | 311,985 |
| 24-05-21 | 4.7 | -0.63% | 445,306 |
| 24-05-20 | 4.73 | +2.83% | 306,316 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotes
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Companyâs lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.
Calendar
2024-06-18
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.56
USD
Average target price
20.33
USD
Spread / Average Target
+345.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.04% | 282M | |
| +64.92% | 62.86B | |
| -1.85% | 41.38B | |
| +45.26% | 40.38B | |
| -8.93% | 27.64B | |
| +13.05% | 26.46B | |
| -21.96% | 18.9B | |
| +4.21% | 12.67B | |
| +25.74% | 12.27B | |
| +27.42% | 12.07B |
- Stock Market
- Equities
- INZY Stock
